Author

R. Jorda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

M. Perina· 4 shared E. Reznickova· 3 shared V. Krystof· 3 shared L. Mada· 2 shared M. Kovalova· 2 shared A. Dolnikova· 1 shared A. M. Tumilovich· 1 shared A. R. Mekhtiev· 1 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

M. Perina

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Characterization of new highly selective pyrazolopyrimidine inhibitor of CDK7

M. Kovalova, L. Havlicek, S. Djukic, J. Skerlova, M. Perina, T. Pospisil, E. Reznickova, P. Rezacova, R. Jorda, V. Krystof

This paper characterizes a new CDK7 inhibitor, LGR6768, showing nanomolar potency and selectivity, with structural and cellular evidence supporting its mechanism and therapeutic potential.

bioRxiv · Feb 24, 2023Cancer Biology

Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines

H. Dostalova, R. Jorda, E. Reznickova, V. Krystof

This study investigates the anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines and finds it inhibits HER2 signaling and downstream kinases.

bioRxiv · Feb 23, 2023Cancer Biology

A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor

M. Perina, M. A. Kiss, G. Motyan, E. Szczyrbova, M. Elias, V. Student, D. Kurfurstova, M. Kovalova, L. Mada, J. Bouchal, E. Frank, R. Jorda

This paper synthesizes and evaluates A-ring-fused pyrazoles derived from dihydrotestosterone as AR antagonists with antiproliferative activity in prostate cancer cells.

bioRxiv · Dec 17, 2022Pharmacology & Toxicology

Synthesis and structural optimization of 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors

M. Tomanova, K. Kozlanska, R. Jorda, L. Jedinak, T. Havlikova, E. Reznickova, M. Perina, P. Klener, A. Dolnikova, P. Cankar, V. Krystof

The paper designs and evaluates 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors, identifying compound 15a with improved selectivity and activity in vitro and in vivo.

bioRxiv · Dec 10, 2022Pharmacology & Toxicology

Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents

A. S. Rudovich, M. Perina, A. V. Krech, M. Y. Novozhilova, A. M. Tumilovich, T. V. Shkel, I. P. Grabovec, M. Kvasnica, L. Mada, M. G. Zavialova, A. R. Mekhtiev, R. Jorda, V. N. Zhabinskii, V. A. Khripach

The paper synthesizes new isoxazolyl steroids and evaluates their anti-prostate cancer activity by testing their effects on androgen receptor signaling and CYP17A1 enzyme activity.

bioRxiv · Oct 28, 2022Pharmacology & Toxicology